<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Specific phobia in adults: Treatment overview</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Specific phobia in adults: Treatment overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Specific phobia in adults: Treatment overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Randi E McCabe, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Bui, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Murray B Stein, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1962228453"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Specific phobia is an anxiety disorder characterized by clinically significant fear of a particular object or situation that typically leads to avoidance behaviors. Phobic fears include animals, insects, heights, water, enclosed places, driving, flying, and choking or vomiting. Some specific phobias involve responses to medical procedures, such as injections, dental work, or blood.</p><p>Specific phobias are among the most common mental disorders and can be highly disabling [<a href="#rid1">1,2</a>]. However, they are also among the most treatable mental disorders [<a href="#rid3">3-6</a>]. Despite availability of effective treatments, the majority of individuals with specific phobias are hesitant to seek treatment [<a href="#rid7">7</a>]. This may be due to lack of knowledge that the phobia is treatable, embarrassment to disclose the phobia to a health professional, accommodation of the phobia through avoidance, or fear of increased anxiety or discomfort in the course of treatment [<a href="#rid5">5</a>].</p><p>The initial management of specific phobia including choosing treatment modality, and subsequent pharmacologic management are reviewed here. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of specific phobias, and treatment of specific phobia with cognitive-behavioral therapy are discussed separately. The management of phobias related to specific clinical procedures (ie, dental phobia, blood and injection phobia, claustrophobia during magnetic resonance imaging [MRI] procedure) are discussed elsewhere as are topics related to specific phobia and anxiety in children and adolescents. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14637.html" rel="external">"Specific phobia in adults: Epidemiology, clinical manifestations, course, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16126.html" rel="external">"Specific phobia in adults: Cognitive-behavioral therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16851.html" rel="external">"Acute procedural anxiety and specific phobia of clinical procedures in adults: Treatment overview"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1226.html" rel="external">"Overview of fears and phobias in children and adolescents"</a>.)</p><p></p><p class="headingAnchor" id="H2261016809"><span class="h1">INITIAL MANAGEMENT DECISIONS</span></p><p class="headingAnchor" id="H3998895374"><span class="h2">To treat or not to treat</span><span class="headingEndMark"> — </span>We use shared decision making in formulating the treatment plan, including whether to treat the specific phobia. We review the impact of the phobia on overall quality of life including level of distress, presence of avoidance behaviors, and interference with daily functioning. In cases where the specific phobia leads to an impact on daily life (eg, work, interpersonal), we encourage treatment. In cases where the impact of the specific phobia is less pervasive or in cases where the phobic stimulus is infrequently encountered, we are guided by the individual preference. In these cases, the patient may decide not to pursue treatment or to pursue a specific form of treatment (eg, as needed pharmacologic management for infrequently encountered stimulus such as a rare airline flight).</p><p>Individuals with a recent diagnosis of specific phobia are often motivated to seek treatment when they learn that effective treatments are available.</p><p class="headingAnchor" id="H3885120816"><span class="h2">Addressing co-occurring anxiety disorders</span><span class="headingEndMark"> — </span>Prior to treating specific phobia, we are sure to do a thorough assessment for common co-occurring disorders such as anxiety disorders, mood disorders, and substance use disorders. We also determine the primary disorder of concern (ie, the disorder that is associated with the greatest distress and/or impairment and/or the one that the patient would like to focus on) and typically focus on its treatment. Presenting symptoms may be due to co-occurring disorders, which, if successfully treated, may improve the presenting symptoms and overall quality of life [<a href="#rid8">8</a>].</p><p>However, some specific phobias may be severe, even life threatening (eg, choking, fear of medical procedures), and thus warrant clinical priority for treatment. (See  <a class="medical medical_review" href="/d/html/108804.html" rel="external">"Management of panic disorder with or without agoraphobia in adults"</a> and  <a class="medical medical_review" href="/d/html/101879.html" rel="external">"Generalized anxiety disorder in adults: Management"</a>.)</p><p class="headingAnchor" id="H2193946721"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H2425836705"><span class="h2">Cognitive-behavioral therapy with exposure: First line for most</span><span class="headingEndMark"> — </span>For most patients with a diagnosis of specific phobia, we suggest first-line treatment with cognitive-behavioral therapy (CBT) that includes exposure rather than other forms of psychotherapy or medication management [<a href="#rid9">9</a>]. Treatment with exposure therapy may be emotionally taxing. Patients may be reluctant to pursue exposure therapy. Strategies to overcome this reluctance are discussed separately. (See  <a class="medical medical_review" href="/d/html/16126.html" rel="external">"Specific phobia in adults: Cognitive-behavioral therapy"</a>.)</p><p class="headingAnchor" id="H2795623017"><span class="h3">Choosing an exposure therapy</span><span class="headingEndMark"> — </span>Exposure therapy methods include in vivo exposure, imaginal exposure, virtual reality exposure. While in vivo exposure has the most evidence supporting it in the treatment of specific phobia, other treatments such as imaginal or virtual reality exposure have a role when the stimulus is infrequent, difficult to recreate, or as part of a hierarchy leading to in vivo exposure.</p><p>Discussion of CBT with exposure for specific phobia in adults, types of exposure, components of CBT, and other cognitive or behavioral interventions are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/16126.html" rel="external">"Specific phobia in adults: Cognitive-behavioral therapy", section on 'Types of exposure'</a> and  <a class="medical medical_review" href="/d/html/16126.html" rel="external">"Specific phobia in adults: Cognitive-behavioral therapy", section on 'Administering exposure therapy'</a>.)</p><p class="headingAnchor" id="H2754698122"><span class="h3">Efficacy of exposure therapy</span><span class="headingEndMark"> — </span>CBT with exposure is an effective treatment for specific phobia. Among psychosocial interventions tested in specific phobia, CBT with exposure has been the most extensively studied in clinical trials [<a href="#rid5">5</a>]. In a meta-analysis of trials, treatment with exposure-based therapy led to greater improvement in symptoms of specific phobia than wait-list control conditions (18 trials, large effect size), placebo treatments (five trials, moderate to large effect size) and active nonexposure interventions (six trials, large effect size). At follow-up, the average subject receiving exposure treatment was doing better than 75 percent of those receiving placebo and 64 percent of those receiving active nonexposure treatment [<a href="#rid5">5</a>].</p><p>Among exposure treatments for specific phobia, in vivo exposure appears to be more effective than other forms of exposure; however, this advantage was not found at follow-up. For example, in a meta-analysis of seven studies in vivo exposure compared with alternative mode of exposure yielded an advantage at posttreatment; however, at follow-up this advantage was no longer supported [<a href="#rid5">5</a>]. Few studies directly compare the efficacy of exposure treatment variations, results are mixed, and heterogeneity of studies limits their interpretation [<a href="#rid5">5,10-16</a>]. Further studies are warranted.</p><p>Additionally, forms of exposure therapy delivered via the internet or mobile-based applications appear to be effective as compared with waitlist or other control conditions [<a href="#rid13">13,17,18</a>].</p><p>There are no randomized clinical trials directly comparing CBT with exposure and medication for specific phobia.</p><p class="headingAnchor" id="H3394911407"><span class="h2">Benzodiazepines as alternative initial treatment</span></p><p class="headingAnchor" id="H1401478062"><span class="h3">Indications and precautions</span><span class="headingEndMark"> — </span>For individuals who are reluctant to undergo CBT (despite being informed about the relative risks, benefits, and supporting evidence), when the phobic stimulus is infrequently encountered and unavoidable (eg, needing to fly for work), or in cases where the exposure therapy is unavailable over the short term (eg, patient with fear of flying presents for treatment one week prior to scheduled flight), we typically use a benzodiazepine to treat the specific phobia. For some patients, the knowledge that they have the medication enables them to overcome the avoidance of flying.</p><p>However, we typically do not combine benzodiazepines with exposure therapy as the sedative properties of the benzodiazepine, may interfere with engagement in exposure treatment. Additionally, they may undermine the efficacy of exposure treatment as patients may believe that they “need” the medication to engage with the phobic stimulus thereby attenuating the effect of the exposure or perpetuating avoidance behaviors [<a href="#rid19">19,20</a>].</p><p>For example, in one trial, the acute and delayed effects of a short-acting benzodiazepine, <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a>, on individuals with a flying phobia was studied; 28 females with a flying phobia were randomly assigned to receive 1 mg of alprazolam or placebo given 1.5 hours prior to a short first flight and then one week later were exposed to another short flight without medication [<a href="#rid21">21</a>]. Individuals treated with alprazolam reported reduced anxiety during the first flight as compared with the placebo treated group. However, on the second flight, individuals who had previously received alprazolam (during the first flight) as compared with those who received placebo, reported greater levels of anxiety and an increased in the number of panic attacks. The conclusion was that alprazolam appears to hinder therapeutic effects of exposure in flying phobia and may lead to increased anxiety at subsequent encounters with the phobic stimulus.</p><p>We advise the patient that using benzodiazepine to manage one feared situation might increase the anxiety in future encounters with that situation, and that once the decision to use benzodiazepine is taken, they will likely be needing it each time. Because of this potential “pharmaco-dependance” effect, and their (unfavorable) side effect profile, the decision to initiate benzodiazepines, even on an as-needed basis, requires carefully weighting risk/benefit ratio with the patient.</p><p>Side effects of benzodiazepines include sedation, impaired psychomotor performance, amnesia, and abuse as well as dependence and withdrawal symptoms after long-term treatment [<a href="#rid22">22</a>]. The risk of misuse of benzodiazepines is largely confined to individuals with a history of or an active substance use disorder; however, a family history of substance abuse may be a risk factor for some individuals [<a href="#rid23">23</a>]. In individuals with a history of prior substance use disorder we discuss the risks of benzodiazepine use and when given, we prefer a benzodiazepine that is longer acting and with slower onset of action (eg, <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">clonazepam</a>) to reduce misuse liability. Additionally, we prescribe the minimum amount of medication. For example, in an individual with a past history of substance use disorder who has a fear of flying and will be flying for work in one week, we would give clonazepam 1 mg tablets, one tablet for each flight without refills.</p><p class="headingAnchor" id="H1937015710"><span class="h3">Choosing and administering benzodiazepines</span><span class="headingEndMark"> — </span>When using benzodiazepines for specific phobia, we prefer to use benzodiazepines with longer acting and with slower onset of action (eg, <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">clonazepam</a>) to limit the risk of substance use disorder. For example, when using clonazepam, we tell the patient to take 1 mg as initial dose one hour prior to the phobic stimulus being encountered.</p><p>However, if the exposure to the feared object or situation is very short lived, we could use a benzodiazepine with shorter onset of action (eg, <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a>), to limit the duration of potential side effects (eg, short flight prior to an important work meeting). In this situation we would use lorazepam 0.5 to 1 mg as the initial dose 30 minutes prior to the phobic stimulus being encountered.</p><p>We advise patients to take a test dose of the prescribed medication prior to using it for the phobic situation to ensure it does not lead to oversedation. Additionally, we advise patients to avoid alcohol, driving and using heavy machinery during the hours after taking the medication. Consuming alcohol with the medication may lead to additive severe side effects such as sedation, confusion, or impaired coordination.</p><p class="headingAnchor" id="H824160848"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>There are no rigorous data from clinical trials reporting that benzodiazepines are effective for specific phobia. In our experience, flying phobia anxiety can be managed with benzodiazepines short term (ie, for the length of a flight); however, well-designed randomized trials are needed to further test their efficacy for specific phobia in general [<a href="#rid10">10,24,25</a>]. Discussion of the use of benzodiazepines in the treatment of acute procedural anxiety or specific phobia of clinical procedures is found elsewhere. (See  <a class="medical medical_review" href="/d/html/16851.html" rel="external">"Acute procedural anxiety and specific phobia of clinical procedures in adults: Treatment overview"</a>.)</p><p class="headingAnchor" id="H272062702"><span class="h1">SUBSEQUENT TREATMENT</span></p><p class="headingAnchor" id="H1315917782"><span class="h2">Robust response</span><span class="headingEndMark"> — </span>Treatment gains from exposure therapy appear to be maintained for at least one year [<a href="#rid26">26-28</a>]. We suggest ongoing self-exposure on a regular basis to maintain treatment gains [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/16126.html" rel="external">"Specific phobia in adults: Cognitive-behavioral therapy", section on 'For robust treatment response and maintenance of gains'</a>.)</p><p>Treatment gains from benzodiazepines last only as long as the patient continues to take the medication, and thus continuing treatment is required.</p><p class="headingAnchor" id="H610025100"><span class="h2">Inadequate response</span></p><p class="headingAnchor" id="H2439626832"><span class="h3">Inadequate response to exposure therapy</span><span class="headingEndMark"> — </span>There are no clinical trials of strategies to treat specific phobia that does not respond to initial treatment with exposure or for those who choose not to participate in exposure therapy due to levels of distress. Our initial step in addressing inadequate response to exposure therapy is to confirm that the individual is not engaging in a behavior that might hinder the efficacy (eg, taking benzodiazepine or drinking alcohol before exposure session). After confirming this we typically add one or more additional components including cognitive therapy, psychoeducation, safety behaviors, anxiety management, and applied tension. (See  <a class="medical medical_review" href="/d/html/16126.html" rel="external">"Specific phobia in adults: Cognitive-behavioral therapy", section on 'For inadequate response to exposure therapy'</a>.)</p><p class="headingAnchor" id="H1930004143"><span class="h3">Inadequate response to pharmacologic management</span><span class="headingEndMark"> — </span>Minimal evidence supports the use of the following agents in the treatment of specific phobia. We do not routinely use these agents; however, in some cases we use them as a treatment of last resort. The choice of the drug is guided by the potential contra-indications (eg, asthma contraindicate beta-blockers), the demonstrated efficacy in conditions with similar phenomenology to the targeted specific phobia (eg, selective serotonin reuptake inhibitor [SSRI] claustrophobia that is similar to panic disorder for which SSRI have demonstrated efficacy), or potential comorbid conditions (SSRI have demonstrated efficacy in generalized anxiety disorder).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta-adrenergic blocking agents</strong> – Although used for social anxiety disorder, performance type, only minimal and conflicting data, supports the use of beta-adrenergic blocking agents in the treatment of specific phobia [<a href="#rid30">30-32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SSRIs </strong>–<strong> </strong>Small clinical trials suggest possible efficacy but have not demonstrated a conclusive benefit [<a href="#rid33">33,34</a>]. May be most useful for situational phobias that are similar to panic disorder (eg, claustrophobia).</p><p></p><p>Minimal evidence supports the use of D-cycloserine [<a href="#rid35">35-40</a>], <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> [<a href="#rid41">41-43</a>], <a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">methylene blue</a> [<a href="#rid44">44</a>], <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> [<a href="#rid45">45</a>] or yohimbine [<a href="#rid30">30</a>] as augmentation agents when administered immediately before CBT exposure sessions.</p><p class="headingAnchor" id="H2454738605"><span class="h1">PERCEIVED HELPFULNESS OF TREATMENT</span><span class="headingEndMark"> — </span>While randomized trials appear to show that treatment of specific phobia is effective, it is unclear if patients experience treatment as helpful or not in clinical practice [<a href="#rid5">5,6,10</a>]. Cross-sectional population-based World Health Organization mental health surveys conducted in 24 countries with a population-based sample of 112,507 assessed the perceived helpfulness of treatment and the persistence of help-seeking after receiving unhelpful treatment in respondents who reported lifetime prevalence of specific phobia [<a href="#rid46">46</a>]. Of that sample, 23 percent found treatment helpful after the first professional seen while the cumulative probability of finding treatment helpful was 85.7 percent after seeing up to nine professionals. The overall proportion of those ever receiving helpful treatment was 47.5 percent, which could have been improved by persistence in help-seeking. This study underscores the need to refer individuals with specific phobia to clinicians skilled in providing evidence-based treatment and to encourage further help seeking if initial attempts are perceived as unsuccessful.</p><p></p><p class="headingAnchor" id="H604006005"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113096.html" rel="external">"Society guideline links: Anxiety and anxiety disorders in adults"</a>.)</p><p class="headingAnchor" id="H2425746104"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific phobia</strong> – Specific phobia is an anxiety disorder characterized by clinically significant fear of a particular object or situation that typically leads to avoidance behaviors. Specific phobias are among the most common mental disorders and can be highly disabling. They are also among the most treatable mental disorders. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management decisions </strong>– We use shared decision making in formulating the treatment plan, including whether to treat. In cases where the specific phobia leads to an impact on daily life (eg, work, interpersonal), we encourage treatment. In cases where the impact of the specific phobia is less pervasive or in cases where the phobic stimulus is infrequently encountered, we are guided by the individual preference. (See <a class="local">'Initial management decisions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Co-occurring disorders </strong>– We prioritize the treatment of co-occurring anxiety disorders such as generalized anxiety disorder, panic disorder, or other comorbid disorders (eg, mood disorder) if they are causing the most distress/impairment or identified by the patient to be of principal concern. Presenting symptoms may be due to co-occurring disorders, which, if successfully treated, may improve the presenting symptoms and overall quality of life. (See <a class="local">'Addressing co-occurring anxiety disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cognitive-behavioral therapy (CBT) as initial treatment</strong> – For most patients newly diagnosed with specific phobia, we suggest first-line treatment with CBT that includes exposure rather than other forms of psychotherapy or medication management (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). While comparative treatment studies are lacking, CBT with exposure appears highly efficacious in most patients. (See <a class="local">'Cognitive-behavioral therapy with exposure: First line for most'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benzodiazepine as alternative initial treatment </strong>– For individuals in which CBT with exposure is unavailable, not tolerated, refused, or in cases where the stimulus is rarely encountered and unavoidable, we suggest treatment with a short-acting benzodiazepine (eg, <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a>) versus other medications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent1">We limit prescriptions of benzodiazepines in patients with a history of a substance use disorder and inform all patients that benzodiazepine might interfere with engagement in exposure therapy and worsen anxiety in future encounters with the feared situation. (See <a class="local">'Benzodiazepines as alternative initial treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593.</a></li><li><a class="nounderline abstract_t">Stinson FS, Dawson DA, Patricia Chou S, et al. The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 2007; 37:1047.</a></li><li><a class="nounderline abstract_t">Davis TE 3rd, Ollendick TH, Ost LG. Intensive Treatment of Specific Phobias in Children and Adolescents. Cogn Behav Pract 2009; 16:294.</a></li><li class="breakAll">Koerner N, Rogojanski J, Antony MM. Specific phobia. In: Cognitive-Behavioral Therapy with Adults: A Guide to Empirically-Informed Assessment and Intervention, Hofmann SG, Reinecke MA (Eds), Cambridge University Press, Cambridge 2010. p.60.</li><li><a class="nounderline abstract_t">Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ. Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev 2008; 28:1021.</a></li><li><a class="nounderline abstract_t">Zlomke K, Davis TE 3rd. One-session treatment of specific phobias: a detailed description and review of treatment efficacy. Behav Ther 2008; 39:207.</a></li><li><a class="nounderline abstract_t">Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50:85.</a></li><li><a class="nounderline abstract_t">Curtis GC, Magee WJ, Eaton WW, et al. Specific fears and phobias. Epidemiology and classification. Br J Psychiatry 1998; 173:212.</a></li><li class="breakAll">Barlow DH, Allen LB, Basden SL. Psychological treatments for panic disorders, phobias, and generalized anxiety disorder. In: A Guide to Treatments That Work, 3rd ed., Nathan PE, Gorman JM (Eds), Oxford University Press, New York 2007. p.351.</li><li><a class="nounderline abstract_t">Choy Y, Fyer AJ, Lipsitz JD. Treatment of specific phobia in adults. Clin Psychol Rev 2007; 27:266.</a></li><li><a class="nounderline abstract_t">Michaliszyn D, Marchand A, Bouchard S, et al. A randomized, controlled clinical trial of in virtuo and in vivo exposure for spider phobia. Cyberpsychol Behav Soc Netw 2010; 13:689.</a></li><li><a class="nounderline abstract_t">Boyd D, Wetterneck C, Hart J. Potential utility of full motion flight simulators for treatment of individuals with a fear of flying. Aviat Space Environ Med 2013; 84:264.</a></li><li><a class="nounderline abstract_t">Mor S, Grimaldos J, Tur C, et al. Internet- and mobile-based interventions for the treatment of specific phobia: A systematic review and preliminary meta-analysis. Internet Interv 2021; 26:100462.</a></li><li><a class="nounderline abstract_t">Hamm AO. Specific phobias. Psychiatr Clin North Am 2009; 32:577.</a></li><li><a class="nounderline abstract_t">Wechsler TF, Kümpers F, Mühlberger A. Inferiority or Even Superiority of Virtual Reality Exposure Therapy in Phobias?-A Systematic Review and Quantitative Meta-Analysis on Randomized Controlled Trials Specifically Comparing the Efficacy of Virtual Reality Exposure to Gold Standard in vivo Exposure in Agoraphobia, Specific Phobia, and Social Phobia. Front Psychol 2019; 10:1758.</a></li><li><a class="nounderline abstract_t">Carl E, Stein AT, Levihn-Coon A, et al. Virtual reality exposure therapy for anxiety and related disorders: A meta-analysis of randomized controlled trials. J Anxiety Disord 2019; 61:27.</a></li><li><a class="nounderline abstract_t">Zimmer A, Wang N, Ibach MK, et al. Effectiveness of a smartphone-based, augmented reality exposure app to reduce fear of spiders in real-life: A randomized controlled trial. J Anxiety Disord 2021; 82:102442.</a></li><li><a class="nounderline abstract_t">Haberkamp A, Walter H, Althaus P, et al. Testing a gamified Spider App to reduce spider fear and avoidance. J Anxiety Disord 2021; 77:102331.</a></li><li><a class="nounderline abstract_t">Otto MW, McHugh RK, Kantak KM. Combined Pharmacotherapy and Cognitive-Behavioral Therapy for Anxiety Disorders: Medication Effects, Glucocorticoids, and Attenuated Treatment Outcomes. Clin Psychol (New York) 2010; 17:91.</a></li><li><a class="nounderline abstract_t">Otto MW, Pollack MH, Sabatino SA. Maintenance of remission following cognitive behavior therapy for panic disorder: Possible deleterious effects of concurrent medication treatment. Behav Ther 1996; 27:473.</a></li><li><a class="nounderline abstract_t">Wilhelm FH, Roth WT. Acute and delayed effects of alprazolam on flight phobics during exposure. Behav Res Ther 1997; 35:831.</a></li><li><a class="nounderline abstract_t">Rickels K, Lucki I, Schweizer E, et al. Psychomotor performance of long-term benzodiazepine users before, during, and after benzodiazepine discontinuation. J Clin Psychopharmacol 1999; 19:107.</a></li><li><a class="nounderline abstract_t">Ciraulo DA, Sands BF, Shader RI. Critical review of liability for benzodiazepine abuse among alcoholics. Am J Psychiatry 1988; 145:1501.</a></li><li class="breakAll">Roy-Byrne PP, Cowley DS. Pharmacological treatments for panic disorder, generalized anxiety disorder, specific phobia, and social anxiety disorder. In: A guide to treatments that work, 3rd ed., Nathan PE, Gorman JM (Eds), Oxford University Press, New York 2007. p.395.</li><li><a class="nounderline abstract_t">Bluemke DA, Breiter SN. Sedation procedures in MR imaging: safety, effectiveness, and nursing effect on examinations. Radiology 2000; 216:645.</a></li><li><a class="nounderline abstract_t">Koch EI, Spates CR, Himle JA. Comparison of behavioral and cognitive-behavioral one-session exposure treatments for small animal phobias. Behav Res Ther 2004; 42:1483.</a></li><li><a class="nounderline abstract_t">Ost LG, Fellenius J, Sterner U. Applied tension, exposure in vivo, and tension-only in the treatment of blood phobia. Behav Res Ther 1991; 29:561.</a></li><li><a class="nounderline abstract_t">Ost LG, Slakovskis P, Hellstrom K. One-session therapist-directed exposure vs. self-exposure in the treatment of spider phobia. Behav Ther 1991; 22:407.</a></li><li><a class="nounderline abstract_t">Al-Kubaisy T, Marks IM, Logsdail S, Marks MP. Role of exposure homework in phobia reduction: A controlled study. Behav Ther 1992; 23:599.</a></li><li><a class="nounderline abstract_t">Meyerbröker K, Morina N, Emmelkamp PMG. Enhancement of exposure therapy in participants with specific phobia: A randomized controlled trial comparing yohimbine, propranolol and placebo. J Anxiety Disord 2018; 57:48.</a></li><li><a class="nounderline abstract_t">Fagerström KO, Hugdahl K, Lundström N. Effect of beta-receptor blockade on anxiety with reference to the three-systems model of phobic behavior. Neuropsychobiology 1985; 13:187.</a></li><li><a class="nounderline abstract_t">Liu HH, Milgrom P, Fiset L. Effect of a beta-adrenergic blocking agent on dental anxiety. J Dent Res 1991; 70:1306.</a></li><li><a class="nounderline abstract_t">Alamy S, Wei Zhang, Varia I, et al. Escitalopram in specific phobia: results of a placebo-controlled pilot trial. J Psychopharmacol 2008; 22:157.</a></li><li><a class="nounderline abstract_t">Benjamin J, Ben-Zion IZ, Karbofsky E, Dannon P. Double-blind placebo-controlled pilot study of paroxetine for specific phobia. Psychopharmacology (Berl) 2000; 149:194.</a></li><li><a class="nounderline abstract_t">Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61:1136.</a></li><li><a class="nounderline abstract_t">Mataix-Cols D, Fernández de la Cruz L, Monzani B, et al. D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data. JAMA Psychiatry 2017; 74:501.</a></li><li><a class="nounderline abstract_t">Kappelmann N, Suesse M, Steudte-Schmiedgen S, et al. D-cycloserine as adjunct to brief computerised CBT for spider fear: Effects on fear, behaviour, and cognitive biases. J Behav Ther Exp Psychiatry 2020; 68:101546.</a></li><li><a class="nounderline abstract_t">Farrell LJ, Waters AM, Oar EL, et al. D-cycloserine-augmented one-session treatment of specific phobias in children and adolescents. Brain Behav 2018; 8:e00984.</a></li><li><a class="nounderline abstract_t">Smits JA, Rosenfield D, Otto MW, et al. D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry 2013; 73:1054.</a></li><li><a class="nounderline abstract_t">Smits JAJ, Pollack MH, Rosenfield D, et al. Dose Timing of D-Cycloserine to Augment Exposure Therapy for Social Anxiety Disorder: A Randomized Clinical Trial. JAMA Netw Open 2020; 3:e206777.</a></li><li><a class="nounderline abstract_t">de Quervain DJ, Bentz D, Michael T, et al. Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci U S A 2011; 108:6621.</a></li><li><a class="nounderline abstract_t">Soravia LM, Heinrichs M, Aerni A, et al. Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci U S A 2006; 103:5585.</a></li><li><a class="nounderline abstract_t">Steudte-Schmiedgen S, Fay E, Capitao L, et al. Hydrocortisone as an adjunct to brief cognitive-behavioural therapy for specific fear: Endocrine and cognitive biomarkers as predictors of symptom improvement. J Psychopharmacol 2021; 35:641.</a></li><li><a class="nounderline abstract_t">Telch MJ, Bruchey AK, Rosenfield D, et al. Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. Am J Psychiatry 2014; 171:1091.</a></li><li><a class="nounderline abstract_t">Diemer J, Domschke K, Mühlberger A, et al. Acute anxiolytic effects of quetiapine during virtual reality exposure--a double-blind placebo-controlled trial in patients with specific phobia. Eur Neuropsychopharmacol 2013; 23:1551.</a></li><li><a class="nounderline abstract_t">de Vries YA, Harris MG, Vigo D, et al. Perceived helpfulness of treatment for specific phobia: Findings from the World Mental Health Surveys. J Affect Disord 2021; 288:199.</a></li></ol></div><div id="topicVersionRevision">Topic 114843 Version 11.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15939837" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17335637" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20161063" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Intensive Treatment of Specific Phobias in Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20161063" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Intensive Treatment of Specific Phobias in Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18410984" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Psychological approaches in the treatment of specific phobias: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18721635" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : One-session treatment of specific phobias: a detailed description and review of treatment efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8427558" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9926096" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Specific fears and phobias. Epidemiology and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9926096" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Specific fears and phobias. Epidemiology and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17112646" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment of specific phobia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21142994" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A randomized, controlled clinical trial of in virtuo and in vivo exposure for spider phobia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23513291" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Potential utility of full motion flight simulators for treatment of individuals with a fear of flying.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34646752" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Internet- and mobile-based interventions for the treatment of specific phobia: A systematic review and preliminary meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19716991" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Specific phobias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31551840" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Inferiority or Even Superiority of Virtual Reality Exposure Therapy in Phobias?-A Systematic Review and Quantitative Meta-Analysis on Randomized Controlled Trials Specifically Comparing the Efficacy of Virtual Reality Exposure to Gold Standard in vivo Exposure in Agoraphobia, Specific Phobia, and Social Phobia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30287083" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Virtual reality exposure therapy for anxiety and related disorders: A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34246153" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effectiveness of a smartphone-based, augmented reality exposure app to reduce fear of spiders in real-life: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33166870" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Testing a gamified Spider App to reduce spider fear and avoidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26855480" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Combined Pharmacotherapy and Cognitive-Behavioral Therapy for Anxiety Disorders: Medication Effects, Glucocorticoids, and Attenuated Treatment Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Maintenance of remission following cognitive behavior therapy for panic disorder: Possible deleterious effects of concurrent medication treatment</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9299803" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Acute and delayed effects of alprazolam on flight phobics during exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10211911" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Psychomotor performance of long-term benzodiazepine users before, during, and after benzodiazepine discontinuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2904227" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Critical review of liability for benzodiazepine abuse among alcoholics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2904227" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Critical review of liability for benzodiazepine abuse among alcoholics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10966690" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Sedation procedures in MR imaging: safety, effectiveness, and nursing effect on examinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15500817" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparison of behavioral and cognitive-behavioral one-session exposure treatments for small animal phobias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1684704" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Applied tension, exposure in vivo, and tension-only in the treatment of blood phobia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : One-session therapist-directed exposure vs. self-exposure in the treatment of spider phobia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Role of exposure homework in phobia reduction: A controlled study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29804894" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Enhancement of exposure therapy in participants with specific phobia: A randomized controlled trial comparing yohimbine, propranolol and placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4047384" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effect of beta-receptor blockade on anxiety with reference to the three-systems model of phobic behavior.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1918581" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of a beta-adrenergic blocking agent on dental anxiety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18208904" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Escitalopram in specific phobia: results of a placebo-controlled pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10805616" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Double-blind placebo-controlled pilot study of paroxetine for specific phobia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15520361" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28122091" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31951819" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : D-cycloserine as adjunct to brief computerised CBT for spider fear: Effects on fear, behaviour, and cognitive biases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30106248" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : D-cycloserine-augmented one-session treatment of specific phobias in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23332511" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32496566" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Dose Timing of D-Cycloserine to Augment Exposure Therapy for Social Anxiety Disorder: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21444799" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Glucocorticoids enhance extinction-based psychotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567641" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Glucocorticoids reduce phobic fear in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33908295" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hydrocortisone as an adjunct to brief cognitive-behavioural therapy for specific fear: Endocrine and cognitive biomarkers as predictors of symptom improvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25018057" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23375006" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acute anxiolytic effects of quetiapine during virtual reality exposure--a double-blind placebo-controlled trial in patients with specific phobia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33940429" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Perceived helpfulness of treatment for specific phobia: Findings from the World Mental Health Surveys.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
